CD274 and non-small cell lung carcinoma: More recently, adjuvant data from the IMpower010 revealed the PD-L1 inhibitor atezolizumab improved disease-free survival (DFS) following resection of PD-L1 positive Stage II and III NSCLC, and has supported expanding role of ICIs in the adjuvant setting [7].